- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Astec LifeSciences' board has approved its consolidated Q1 results. Revenue from operations for the quarter ended June 30, 2026, stood at ₹83.56 Cr. The company reported a net loss of ₹18.71 Cr, with Basic EPS at ₹(8.40) for the quarter.